Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00091416 · ClinicalTrials.gov registry record · Phase 1

Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
70
Enrollment target
8
Study locations

NCT00091416 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 70 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (84% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00091416, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
70 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVADV014-00-VP, when given as a vaccine booster to HIV uninfected adults who participated in HVTN 052.

Conditions Studied

HIV Infections

Interventions

  • BIOLOGICAL VRC-HIVADV014-00-VP

Study Locations (8)

New York

  • HIV Prevention & Treatment CRS - New York
  • Univ. of Rochester HVTN CRS - Rochester

Maryland

  • Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore - Baltimore

Massachusetts

  • Fenway Community Health Clinical Research Site (FCHCRS) - Boston

Missouri

  • Saint Louis Univ. School of Medicine, HVTU - St Louis

Rhode Island

  • Miriam Hospital's HVTU - Providence

Tennessee

  • Vanderbilt Vaccine CRS - Nashville

Washington

  • FHCRC/UW Vaccine CRS - Seattle

Trial Details

FieldValue
Enrollment Target 70 participants
Est. Completion 2006-05
Phase Phase 1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00091416

The ClinicalTrials.gov registry entry for NCT00091416 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (84% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which VRC-HIVADV014-00-VP is the first listed.

NCT00091416 reports 8 study locations spanning 7 distinct geographic areas - top geographies include New York, Maryland, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00091416 about?

NCT00091416 is a clinical study titled "Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052". The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVADV014-00-VP, when given as a vaccine booster to HIV uninfected adults who participated in HVTN 052.

What is the current status of trial NCT00091416?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. Estimated completion is 2006-05.

What conditions does trial NCT00091416 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00091416?

The interventions under investigation include: VRC-HIVADV014-00-VP (BIOLOGICAL).

Who is sponsoring clinical trial NCT00091416?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00091416 being conducted?

This trial has 8 study locations across Maryland, Massachusetts, Missouri, New York, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.